Last updated on May 2020

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors


Brief description of study

The purpose of this study is to evaluate MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Detailed Study Description

This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Clinical Study Identifier: NCT03530397

Find a site near you

Start Over

Research Site

Melbourne, Australia
2.34miles
  Connect »

Research Site

Heidelberg, Australia
9.11miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.